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ORIGINAL INVESTIGATION
Effect of liraglutide on cardiac function 
in patients with type 2 diabetes mellitus: 
randomized placebo-controlled trial
Maurice B. Bizino1*, Ingrid M. Jazet2, Jos J. M. Westenberg1, Huub J. van Eyk2, Elisabeth H. M. Paiman1, 
Jan W. A. Smit3 and Hildebrandus J. Lamb1
Abstract 
Background: Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test 
efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without 
cardiovascular disease.
Methods: Patients with DM2 were randomly assigned to receive liraglutide 1.8 mg/day or placebo in this double-
blind trial of 26 weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak 
flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated 
LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and 
peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using 
ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported.
Results: 23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide 
significantly reduced E (− 56 mL/s (− 91 to − 21)), E/A ratio (− 0.17 (− 0.27 to − 0.06)), Edec (− 0.9 mL/s2 * 10−3 (− 1.3 
to − 0.2)) and E/Ea (− 1.8 (− 3.0 to − 0.6)), without affecting A (3 mL/s (− 35 to 41)) and Ea (0.4 cm/s (− 0.9 to 1.4)). 
Liraglutide reduced stroke volume (− 9 mL (− 16 to − 2)) and ejection fraction (− 3% (− 6 to − 0.1)), but did not 
change cardiac output (− 0.4 L/min (− 0.9 to 0.2)), cardiac index (− 0.1 L/min/m2 (− 0.4 to 0.1)) and peak ejection rate 
(− 46 mL/s (− 95 to 3)).
Conclusions: Liraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. 
LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-
induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages.
Trial registration ClinicalTrials.gov: NCT01761318.
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Introduction
Patients with type 2 diabetes mellitus (DM2) are at 
increased risk for heart failure, even in the absence of 
coronary artery disease and hypertension. This so-called 
diabetic cardiomyopathy is characterized by left ventric-
ular (LV) diastolic dysfunction [1] and has an estimated 
prevalence of approximately 50% [2]. When heart failure 
symptoms have developed, most patients with diabetic 
cardiomyopathy are classified as heart failure with pre-
served ejection fraction (HFpEF). HFpEF poses patients 
with  DM2 at a very high morbidity [3] and mortality 
risk [4]. Therefore, early detection followed by medi-
cal therapy to reverse LV diastolic dysfunction seems an 
attractive goal in diabetes management. Although intense 
glycaemic control is a primary tool to reduce diabetes 
complications, tight glucoregulation by itself does not 
seem to improve LV diastolic function [5]. Nor are there 
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any specific drugs besides diuretics that can be used to 
treat or prevent HFpEF [6].
The anti-diabetic agent liraglutide is a glucagon-like 
peptide-1 receptor agonist (GLP-1RA) that improves 
insulin secretion, suppresses glucagon production and 
induces weight loss. Although some studies have inves-
tigated the effect of GLP-1RA on ischemic heart disease 
and symptomatic heart failure with reduced ejection 
fraction (HFrEF) [7], little is known about the effect on 
LV diastolic function. GLP-1RA induced weight loss by 
itself might improve LV diastolic function [8]. In addi-
tion, a direct cardio-protective effect of GLP-1RA ther-
apy has been suggested by preclinical studies and in some 
but not all human studies [9].
Cardiac magnetic resonance imaging (CMR) has been 
shown to enable accurate assessment of LV diastolic and 
systolic function with very high reproducibility [10, 11]. 
Therefore, the purpose of this randomized placebo con-
trolled trial was to evaluate the effect of the GLP1-RA 
liraglutide on CMR-derived indices of cardiac function in 
patients with DM2 without prior cardiovascular disease.
Methods
Study design and participants
The MAGNA VICTORIA (MAGNetic resonance Assess-
ment of VICTOza efficacy in the Regression of cardio-
vascular dysfunction In type 2 diAbetes mellitus) study 
was an investigator-initiated randomized, double-blind, 
assessor-blinded, placebo-controlled, single-center clini-
cal trial with 26 weeks follow-up. Men and women with 
DM2 were eligible if aged 18–69  years. Inclusion crite-
ria were: BMI 25 kg/m2 or above; glycated haemoglobin 
(HbA1c) level of 7.0 to 10.0% (53–86 mmol/mol) despite 
use of maximally tolerable metformin treatment, with or 
without sulphonyurea derivative (SUD) and/or insulin, 
with stable dosage in the 3  months before study entry; 
blood pressure < 150/85  mmHg and stable for at least 
1 month. Due to lack of eligible patients use of SUD and 
insulin was added to inclusion criteria after commence-
ment of the trial. Exclusion criteria were: use of other 
glucose-lowering therapy than mentioned above; history 
or presence of renal, hepatic or cardiovascular disease; 
gastric bypass surgery; chronic pancreatitis or previous 
acute pancreatitis; pregnant or lactating women; and 
contra-indications for MRI. The trial was approved by 
the local ethics committee and performed in accordance 
with the principles of the revised Declaration of Helsinki. 
Written informed consent was obtained from all par-
ticipants before study entry. The trial was conducted at 
the Leiden University Medical Center (LUMC), Leiden, 
the Netherlands, and was registered at clinicaltrials.gov 
(NCT01761318).
Study procedures
Screening visit
Participants underwent pre-screening by telephone to 
assess eligibility on the basis of drug use, medical his-
tory, and anthropometric measures. If potentially eligi-
ble, participants were submitted to a screening visit with 
detailed history taking with special interest to cardiovas-
cular symptoms and presence of neuropathy (peripheral 
sensory neuropathy as detected by monofilament testing 
and/or erectile dysfunction), nephropathy (micro-albu-
minuria) and retinopathy. Height, weight and blood pres-
sure were measured and physical examination, resting 
electrocardiogram (ECG) and blood examination were 
performed. The nonattendance of cardiovascular disease 
was defined as absence of symptoms related to coronary 
artery disease and heart failure and normal ECG.
Randomization and masking
Patients were randomized to liraglutide (Victoza, Novo 
Nordisk A/S, Bagsvaerd, Denmark) or placebo (provided 
by Novo Nordisk A/S, Bagsvaerd, Denmark) once daily 
subcutaneous injections, added to their pharmacologic 
treatment at study entry. Participants were randomized 
with 1:1 stratification for sex and insulin use (block size of 
4) to increase likelihood of comparable groups given the 
relatively low sample size. Randomization was performed 
by the local research pharmacist (Department of Clinical 
Pharmacy, LUMC, Leiden, The Netherlands) after inves-
tigator had provided information on sex and insulin use 
(directly after results of the screening visit). All investi-
gators, study personnel and participants were blinded to 
treatment allocation until the study had been completed 
(including CMR post-processing and analyses).
Study protocol
Study drug was uptitrated from 0.6 mg in the first week, 
1.2 mg in the second week and 1.8 mg from week three 
on (if well-tolerated). Study drug dosage was reduced if 
necessitated by adverse events. Patients were instructed 
to return their used study drug pens in order to calculate 
compliance. In order to prevent hypoglycaemia, an indi-
vidualised adjustment was made regarding concomitant 
glucose-lowering drugs at study entry, based on hypo-
glycaemic events prior to the study and HbA1c value 
at screening visit. Patients using insulin were encour-
aged to perform ambulant glucose monitoring accord-
ing to clinical practice guidelines, and participants not 
using insulin were provided with an ambulant glucose 
meter to perform once weekly fasting glucose and upon 
hypoglycaemic symptoms. Patients had contact to study 
investigators once weekly by telephone, and a study visit 
once monthly. Weight and blood pressure (average of 
2–3 measurements using automatic calibrated device in 
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supine position) were measured at each study visit. Dur-
ing the study, glycaemic drugs were titrated according to 
clinical practice guidelines by means of dose adjustment 
of insulin and/or SUD. Adjustment of antihypertensive 
and lipid-lowering drugs were made if necessary. At study 
entry, week 12 and at end of study, blood examinations 
were performed after at least six hours of fasting. HbA1c 
was measured with boronate affinity high-performance 
liquid chromatography (Primus Ultra, Siemens Health-
care Diagnostics, Breda, the Netherlands) throughout 
the first part of the study. The laboratory chose to change 
their HbA1c measurement method for logistic reasons 
while our study was ongoing. The method was changed 
into ion-exchange high-performance liquid chromatog-
raphy (HPLC) (Tosoh G8, Sysmex Nederland B.V., Etten-
Leur, the Netherlands). HbA1c values were corrected on 
the basis of the correlation coefficient that was derived 
from a validation experiment that used data of 196 sam-
ples that were measured on both analysers (data can be 
provided on request). All other blood samples were cen-
trifuged and stored at − 80 °C until analysis. Serum cre-
atinine, triglyceride, total cholesterol, HDL-cholesterol, 
LDL-cholesterol (Friedewald formula) and N-terminal 
prohormone of brain natriuretic peptide (NTproBNP) 
concentrations were measured on a Modular P800 ana-
lyser (Roche Diagnostics, Mannheim, Germany).
CMR protocol
All participants underwent a cardiac MRI protocol using 
a clinical 3 Tesla Ingenia whole-body MR system (Philips 
Medical Systems, Best, the Netherlands) at baseline and 
follow-up. Subjects were scanned in supine position. The 
body coil was used for transmission, and reception was 
achieved with a 16-element anterior, and a 12-element 
posterior array. The heart was imaged in 2-chamber, 
4-chamber and short-axis views with ECG-gated breath-
hold balanced steady state free-precession cine imaging. 
Then, whole-heart 4D velocity encoded flow MRI was 
performed as described elsewhere [12]. For visualisa-
tion of prior myocardial scarring, a free-breathing high 
spatial resolution delayed enhancement phase-sensitive 
inversion recovery sequence was acquired after intra-
venous administration of gadolinium contrast material 
(0.3 mL/kg, Dotarem; Guerbet, Bloomington, USA) [13]. 
All images were blinded for study participant and occa-
sion (baseline or follow-up). Image post-processing was 
performed using validated MASS software (LUMC, Lei-
den, the Netherlands). LV diastolic function comprised 
of early peak mitral annular septal tissue velocity (Ea 
in cm/s) which was analysed with the use of 4 chamber 
long-axis view. Early (E) and late (A) peak transmitral 
flow rate (in mL/s) and E/A ratio were analysed using 
4D flow dataset with retrospective valve tracking [12]. E 
deceleration peak (Edec) was defined as the maximum 
downward slope of early peak flow rate. E (in cm/s, with-
out background subtraction) divided by Ea is a validated 
estimate of LV filling pressure [14]. Short axis cine images 
were used to measure LV systolic function parameters: 
stroke volume, ejection fraction, cardiac output and car-
diac index (cardiac output/body surface area). The LV 
systolic function parameter peak ejection rate was meas-
ured with 4D flow MRI. The heart rate during MRI scan 
was chosen to report because that heart rate most closely 
reflects cardiac dynamics as assessed with MRI. LV filling 
volume was analysed with 4D flow. LA volume was calcu-
lated using Simpsons rule [10] and then divided by body 
surface area to obtain LA volume index. LV end-diastolic 
volume (LVEDV), LV end-systolic volume (LVESV) and 
LV mass (LVM) were all obtained from short axis cine 
imaging studies. Parameters LV mass index (LV mass/
body surface area) and LVMI/LVEDVI (LV mass index/
LVEDV index) and LV compliance (LVEDV/E/Ea) were 
calculated.
Study endpoints
Since integrative assessment of cardiac function encom-
passes both LV diastolic and systolic indices, all were 
marked as primary endpoint. However, for sample size 
calculation (see below) Edec  and LV ejection fraction 
were used. Predefined secondary endpoint were blood 
pressure, body weight, HbA1c, LVEDV, LVESV, LVM, 
LVMI, LVMI/LVEDVI. Other pre-specified endpoints 
were creatinine and NTproBNP. Endpoints that were not 
predefined were heart rate, LV filling volume, LA volume, 
LA volume index and LV compliance. We chose to report 
these endpoints for interpretation purposes.
Statistical analysis
Sample size was calculated based on a publication on the 
effects of pioglitazone on cardiac function parameters 
[15] (for Edec),  and on a study describing the effect of 
GLP-1RA in patients with DM2 with heart failure with 
reduced ejection fraction [16] (for ejection fraction). We 
estimated that for a power of 90%, α of 0.05 and mini-
mum expected difference of 25% (SD20%), we would 
need a sample size of 9 to 17 patients per treatment arm. 
Furthermore, taking into consideration that the study 
population in our trial would have a significantly bet-
ter systolic function than the patients with heart failure 
studied in the trial mentioned above, differences might 
be smaller. Finally, assuming a 10% loss to follow-up, we 
aimed to include 25 patients per group. Data are shown 
as mean ± SD, or as median (interquartile range) when 
not normally distributed. For all presented study end-
points, we performed an intention-to-treat analysis of 
covariance (ANCOVA) of between-group differences 
Page 4 of 12Bizino et al. Cardiovasc Diabetol           (2019) 18:55 
of change from baseline with randomization arm as the 
independent variable and the baseline measurement of 
dependent variable as a covariate. Statistical analyses 
were performed using SPSS version 23.0 for Windows 
(IBM Corporation, Chicago, IL). A P value < 0.05 was 
considered statistically significant.
Role of the funding source
Novo Nordisk (Denmark) funded this investigator-initi-
ated study. Novo Nordisk had no role in the design of the 
study, data collection, data analysis, data interpretation, 
or writing of the report. All authors had access to all the 
data and final responsibility for the decision to submit for 
publication.
Results
Participants were enrolled between December 2013 and 
September 2015 with last patient last visit in March 2016. 
Figure  1 shows the trial profile and baseline character-
istics are shown in Table  1. Sex, insulin use, age, blood 
pressure, use of anti-hypertensive drugs, lipid levels, 
smoking history and glycaemic control were compa-
rable in both groups. Liraglutide patients had slightly 
higher BMI (+ 1.0 kg/m2). There was an uneven distribu-
tion of nephropathy (9% in liraglutide versus 42% in pla-
cebo group). With regard to primary outcome measures 
there was slightly higher E/A ratio (+ 0.05) and lower E/
Ea (− 0.6) in liraglutide versus placebo at baseline. In the 
liraglutide group uptitration was delayed in five patients 
versus none in placebo group, and study drug dose that 
patients used was 0.6  mg (n = 2); 1.2  mg (n = 3) and 
1.8 mg (n = 18). In placebo group, no patient had delayed 
uptitration and all patients used 1.8  mg once daily. The 
cumulative prescribed study drug dose was 278.4 ± 45 mg 
in liraglutide versus 302.4 ± 13.8 mg in placebo with com-
pliance of 98% (± 3) versus 96% (± 4). 
Concomitant glucose‑lowering drugs
In liraglutide group use of SUD decreased from 26% 
at baseline to 18% at 26  weeks, and the use of insulin 
decreased from 70 ± 46 to 54 ± 43  IU/day (percentage 
of participants on insulin therapy decreased from 65 to 
64%). In placebo group use of SUD increased from 31 to 
40%. Number of insulin users increased from 65 to 72% 
with average daily dose of 69 IU at baseline and 69 IU at 
26 weeks.
Anthropometric and laboratory values
Liraglutide group had significantly more weight loss 
than placebo group (− 4.3 ± 3.8  kg vs 0.1 ± 2.5  kg, 
p < 0.001). Systolic and diastolic blood pressure changes 
were not different amongst treatment groups (p = 0.63 
and p = 0.23 respectively). In both liraglutide and pla-
cebo treated patients an improvement in glycaemic con-
trol was noticed. In liraglutide group HbA1c decreased 
1.1 ± 1.0% (11.6 ± 11.1  mmol/mol) versus 0.7 ± 0.9% 
(7.7 ± 9.4  mmol/mol) decline in placebo group, with 
no significant difference between group changes (esti-
mated mean treatment difference: − 2.9 with 95% CI 
from − 8.1 to 2.3  mmol/mol, p = 0.27). Serum creati-
nine slightly increased in both treatment groups but 
there was no difference between group changes (liraglu-
tide: + 4 ± 5 μmol/L; placebo: + 4 ± 5 μmol/L, p = 0.69). 
NTproBNP levels declined from 45 ± 30 to 37 ± 18 pg/
mL in liraglutide group, and increased in placebo 
group from 39 ± 29 to 45 ± 29  pg/mL, with estimated 
mean treatment difference of − 10 pg/mL with 95% CI 
between − 20 and 1 pg/mL, p = 0.07.
Magnetic resonance imaging and spectroscopy
In one patient in the liraglutide  group a small area of 
delayed contrast enhancement was noted in the infer-
oposterior basal segment. On further examination by 
cardiologist there was no sign of cardiac ischemia during 
exercise testing. All other patients had no late gadolinium 
enhancement.
Primary endpoints are shown Table  2 and Fig.  2. LV 
diastolic function indices that changed significantly 
between groups were E, E/A ratio, Edec and E/Ea. All 
these parameters were reduced by liraglutide, as com-
pared with placebo. A and Ea were not affected by treat-
ment. LV systolic function parameters that changed 
significantly between groups were stroke volume and 
ejection fraction. Despite a reduction in these param-
eters, cardiac output and cardiac index did not change 
between groups, due to increased heart rate (Fig. 3).
Table  3 displays non-primary outcome measures. In 
line with reduced stroke volume, the LV filling volume 
is also reduced in liraglutide as compared to placebo. 
Furthermore, LVM significantly decreased in liraglutide 
compared to placebo, but when corrected for reduced 
body surface area (LVMI) this difference did not persist. 
LVEDV was significantly reduced by liraglutide as com-
pared to placebo treated patients. LV compliance showed 
a non-significant trend towards increased compliance in 
liraglutide versus placebo (Fig. 4).
Safety
One patient in the liraglutide group developed edema 
after starting calcium channel blockers. There were no 
patients that developed (symptoms of ) heart failure dur-
ing the study. There were three serious adverse events 
that were not related to study drug use. Other adverse 
events were mild and predominantly of gastro-intestinal 
Page 5 of 12Bizino et al. Cardiovasc Diabetol           (2019) 18:55 
71 patients screened
23 exposed to liraglutide
22 completed treatment
23 analysed in ITT population
1 did not
receive liraglutide
26 exposed to placebo
50 randomised
 • 13 women taking background insulin
 • 7 women not taking background insulin
 • 20 men taking background insulin 
 • 10 men not taking background insulin
1 discontinued treatment 1 discontinued treatment
25 completed treatment
26 analysed in ITT population
24 randomised to receive liraglutide
 • 6 women taking background insulin
 • 3 women not taking background insulin
 • 10 men taking background insulin 
 • 5 men not taking background insulin
26 randomised to receive placebo
 • 4 women taking background insulin
 • 7 women not taking background insulin
 • 10 men taking background insulin 
 • 5 men not taking background insulin
21 not randomised
 • did not meet HbA1c criteria (n=12)
 • claustrophobia (n = 3)
 • cardiac abnormalities (n=3)
 • declined to participate (n=1)
 • other (n=2)
Fig. 1 Trial profile. Patients were randomized with stratification according to sex and insulin use. One patient in liraglutide group withdrew 
consent before he ever received study drug. This patient was therefore not included in intention-to-treat analysis. In another patient assigned to 
liraglutide, withdrawal had taken place upon repeated hypoglycaemic events (on further examination this patient had positive anti-glutamic acid 
decarboxylase autoantibody titer and undetectable c-peptide levels consistent with type 1 diabetes mellitus). In the placebo group, one patient 
was lost to follow-up because he was in detention. All other patients reached end of study. ITT intention-to-treat
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origin. There were no cases of acute pancreatitis during 
the study period.
Discussion
This study shows that in patients with type 2 diabetes 
mellitus without prior cardiovascular disease, 6-month 
treatment with liraglutide improved E/Ea, as compared 
with placebo added to standard care. As such, liraglu-
tide beneficially influenced a key pathogenic hallmark 
of HFpEF: left ventricular filling pressure. Liraglutide 
did not improve left ventricular myocardial relaxation 
(Ea). Liraglutide reduced left ventricular systolic func-
tion parameters stroke volume and ejection fraction, and 
these remained within normal range.
Interpretation
Diabetes with or without the presence of hypertension 
is independently associated with abnormal LV dias-
tolic filling pattern [1], i.e. diabetic cardiomyopathy. The 
asymptomatic stage can persist during years or decades, 
but once symptomatic heart failure has developed, pro-
gressive impairment of myocardial relaxation results in 
compensatory rise in E/Ea to ensure sufficient LV filling 
during diastole. These final stages of HFpEF are charac-
terized by impaired quality of life and life expectancy [6]. 
The early asymptomatic stage with prevalence up to 50% 
[2] therefore seems a window of opportunity to reverse or 
delay progression of diabetic cardiomyopathy. However, 
there are no pharmacologic agents that have unequivo-
cally shown benefit in HFpEF patients [17]. An anti-dia-
betic agent that positively affects HFpEF indices would 
therefore be of great clinical importance. In that regard, 
the observed reduction in E/Ea, is a promising prospect. 
Elevated filling pressure has been shown to indepen-
dently predict progression of HFpEF in patients with 
DM2 [18]. Possible underlying cardiac pathologic mecha-
nisms include wall stress, diffuse cardiac fibrosis and LV 
hypertrophy [19]. Liraglutide seems to positively affect 
these pathologic pathways, as evidenced by reduced E/
Ea, LVM, and a trend towards improved LV compliance 
and NTproBNP levels, as compared to placebo. As such, 
it might be postulated that initiation of liraglutide treat-
ment in the early asymptomatic stage of diabetic cardio-
myopathy, could delay the onset of clinically significant 
HFpEF. With regard to systolic function, we hypothesize 
that reduced LV filling volume directly results in reduced 
stroke volume and ejection fraction. The modest decline 
of ejection fraction is not considered clinically relevant 
in this specific study cohort, because it remained within 
normal range [11]. Furthermore, cardiac output and car-
diac index did not change due to rise in heart rate which 
is a well-documented finding in studies with GLP-1RA 
therapy [9].
Table 1 Baseline characteristics of trial population
E early transmitral peak flow rate, A late transmitral peak flow rate, Edec peak 
deceleration of transmitral early peak flow, Ea early peak mitral annular septal 
tissue velocity
a Macrovascular complications were cerebrovascular or peripheral artery 
disease and not cardiovascular
Liraglutide 
(n = 23)
Placebo 
(n = 26)
Demographics
 Age in years  (SD) 60 (6) 59 (7)
 Male 14 (61%) 15 (58%)
 Diabetes duration in years (SD) 11 (6) 11 (7)
 Diabetes complications
  Retinopathy, n 4 (17%) 2 (8%)
  Nephropathy, n 2 (9%) 11 (42%)
  Neuropathy 10 (44%) 7 (27%)
  Macrovasculara 2 (9%) 0 (0%)
Clinical parameters
 Weight in kg (SD) 98 (14) 94 (13)
 Body-mass index in kg/m2 (SD) 32.6 (4.4) 31.6 (3.4)
 Systolic blood pressure in mmHg (SD) 141 (14) 141 (15)
 Diastolic blood pressure in mmHg (SD) 86 (6) 87 (11)
 Glycated haemoglobin A1c in % (SD) 8.4 (1.1) 8.2 (1.0)
 Glycated haemoglobin A1c in mmol/mol (SD) 67 (12) 65 (10)
 Serum creatinine in μmol/L (SD) 73 (19) 68 (17)
 Urinary albumin/creatinine ratio in mmol/
μg (SD)
1.0 (1.3) 5.0 (8.9)
 Triglycerides in mmol/L (SD) 2.2 (1.5) 2.1 (1.1)
 Total cholesterol in mmol/L (SD) 4.8 (1.0) 4.8 (1.0)
 HDL-c in  mmol/L (SD) 1.2 (0.2) 1.3 (0.4)
 LDL-c in mmol/L (SD) 2.6 (0.9) 2.5 (0.9)
Smoking history
 Never smoked, n 10 (44%) 8 (31%)
 Current smoker, n 4 (17%) 5 (19%)
 Ex-smoker, n 9 (39%) 13 (50%)
Concomitant drug use
 Metformin dose in g/day (SD) 2.1 (0.7) 2.0 (0.5)
 Sulfonylurea, n 6 (26%) 8 (31%)
 Insulin, n 15 (65%) 17 (65%)
 Anti-lipidaemic, n 21 (91%) 19 (73%)
 Anti-hypertensive, n 18 (78%) 20 (77%)
LV diastolic function
 E in mL/s (SD) 331 (99) 325 (96)
 A in mL/s (SD) 367 (79) 371 (70)
 E/A ratio (SD) 0.95 (0.44) 0.90 (0.31)
 Edec in mL/s2 × 10−3 (SD) 2.9 (0.9) 2.6 (1.2)
 Ea in cm/s (SD) 6.0 (1.6) 6.0 (1.8)
 E/Ea (SD) 7.3 (2.9) 7.9 (2.3)
LV systolic function
 Stroke volume in mL (SD) 81 (16) 76 (18)
 Ejection fraction in % (SD) 55 (5.8) 55 (4.5)
 Cardiac output in L/min (SD) 5.4 (0.9) 5.5 (1.0)
 Cardiac index in L/min/m2 (SD) 2.5 (0.3) 2.6 (0.4)
 Peak ejection rate in mL/s (SD) 442 (96) 415 (92)
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Table 2 Primary outcome measures
Within group and between group changes in left ventricular diastolic and systolic function between baseline and 26 weeks (primary outcome)
E early transmitral peak flow rate, A late transmitral peak flow rate, Edec early deceleration peak of transmitral flow rate, Ea early peak mitral annular septal tissue 
velocity
Mean (SD) change from baseline to 26 weeks Mean (95% CI) changes from baseline 
(liraglutide vs placebo)
P value
Liraglutide (n = 23) Placebo (n = 26)
LV diastolic function
 E in mL/s (SD) − 33 (59) 23 (62) − 56 (− 91 to − 21) 0.002
 A in mL/s (SD) 31 (77) 23 (62) 3 (− 35 to 41) 0.88
 E/A (SD) − 0.19 (0.31) − 0.00 (0.17) − 0.17 (− 0.27 to − 0.06) 0.003
 Edec in mL/s2 ×  10−3 (SD) − 0.6 (0.6) 0.3 (0.9) − 0.9 (− 1.3 to − 0.4) < 0.001
 Ea in cm/s (SD) 0.4 (1.8) − 0.2 (1.7) 0.4 (− 0.6 to 1.4) 0.40
 E/Ea (SD) − 0.9 (2.6) 0.6 (1.9) − 1.8 (− 3.0 to − 0.6) 0.005
LV systolic function
 Stroke volume in mL (SD) − 4 (13) 5 (12) − 9 (−16 to −2) 0.02
 Ejection fraction in (% (SD) − 1 (5) 1 (5) − 3 (−6 to − 0.1) 0.02
 Cardiac output in L/min (SD) 0.0 (0.9) 0.3 (1.1) − 0.4 (− 0.9 to 0.2) 0.21
 Cardiac index in L/min/m2 (SD) − 0.0 (0.4) 0.1 (0.5) − 0.1 (− 0.4 to 0.1) 0.27
 Peak ejection rate in mL/s (SD) − 28 (89) 24 (82) − 46 (−95 to 3) 0.07
p = 0.002 p = NS
p = 0.005p = 0.001
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Fig. 2 LV diastolic function. Bar graphs of MR-derived indices of LV diastolic function. Blue bars indicate baseline measurement and red bars 
follow-up. Ea reflects the early peak longitudinal annular motion that is dependent on LV myocardial relaxation. E/Ea is the MR estimate of LV filling 
pressure. NS not significant
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Possible mechanisms
The design of our study did not facilitate unravelling the 
mechanism by which liraglutide reduced E/Ea. There 
are several potential mechanisms to be addressed. First, 
liraglutide has been shown to have natriuretic [20] and 
vasodilatory [21] effect which could have lowered E/
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Fig. 3 LV systolic function. Bar graphs of MRI-derived indices of systolic function. Blue bars indicate baseline measurement and red bars follow-up. 
In the liraglutide group stroke volume decreased, whereas cardiac index remained unchanged because of the increased heart rate. Bpm beats per 
minute
Table 3 Heart rate and heart dimensions
bpm beats per minute, LA left atrial, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVM left ventricular mass index, LVMI left 
ventricular mass index, LVEDVI left ventricular end diastolic volume index
Liraglutide (n = 23) Placebo (n = 26) Mean (95% CI) 
changes from baseline 
(liraglutide vs placebo)
p value
Baseline 26 week Mean (SD) 
change 
from baseline
Baseline 26 week Mean (SD) 
change 
from baseline
Heart rate in bpm (SD) 72 (9) 75 (10) 4 (8) 77 (13) 76 (13) − 1 (6) 4.3 (0.2 to 8) 0.04
LV filling volume in 
mL (SD)
82 (17) 76 (17) − 5 (15) 74 (17) 82 (21) 7 (10) − 11 (− 18 to − 3) 0.01
LA volume index in mL/
m2 (SD)
36 (8) 35 (7) − 1 (6) 32 (8) 34 (10) 1 (7) − 2 (− 6 to 2) 0.38
LVEDV in mL (SD) 147 (25) 141 (25) − 5 (14) 138 (33) 144 (38) 6 (16) − 11 (− 20 to − 2) 0.02
LVESV in mL (SD) 67 (14) 66 (14) − 0 (9) 62 (17) 63 (20) 1 (9) − 1 (− 7 to 4) 0.69
LVM in g (SD) 107 (18) 105 (18) − 2 (8) 108 (27) 110 (29) 4 (9) − 6 (− 11 to − 1) 0.03
LVMI in g/m2 (SD) 49 (6) 49 (6) − 0 (3) 50 (11) 52 (12) 2 (4) − 1.5 (−3.6 to 0.6) 0.17
LVMI/LVEDVI g/mL/
m2 (SD)
0.73 (0.10) 0.75 (0.11) 0.01 (0.07) 0.79 (0.14) 0.77 (0.14) − 0.00 (0.08) 0.01 (− 0.03 to 0.06) 0.60
LV compliance (SD) 23.4 (10.4) 24.1 (8.3) 0.7 (9.7) 19.5 (8.0) 18.6 (8.2) − 0.3 (6.8) 3 (− 1 to 7) 0.14
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Ea by reducing cardiac preload. Second, the increase in 
heart rate could have affected LV diastolic filling pat-
tern directly [22]. However, there are two reasons why 
we do not expect increased heart rate to be the causa-
tive effect of diastolic filling pattern changes: 1. the 
change in heart rate is relatively small in comparison to 
change in early filling; 2. a study in HFpEF patients using 
the selective sino-atrial node blocker ivabradine did not 
change E/Ea [23]. Lastly, a direct effect of GLP-1RA on 
the heart has been proposed as a mechanism to improve 
cardiac energy metabolism and thereby cardiac func-
tion. Although GLP-1 receptor is expressed in cardio-
myocytes, to date it is uncertain what its exact function 
in humans is [24]. However, if liraglutide had improved 
myocardial relaxation, an increase in Ea would have been 
expected. Ea however did not change significantly, which 
suggests against a direct effect of liraglutide on cardiomy-
ocyte relaxation properties. It is unlikely that weight loss 
explains the observed effect of liraglutide on LV diastolic 
function, because a previous study from our group [25] 
has shown that calorie restriction with significant weight 
loss increased E/A ratio probably as a result of improved 
LV relaxation and/or filling properties (since LV filling 
pressure remained unchanged). Another important car-
diovascular effect of weight loss in the study by Hammer 
et  al. was a significant decline in heart rate, which is a 
consistent finding in patients after weight loss. Therefore, 
the rise in heart rate in the present study is in keeping 
with the hypothesis that other mechanisms than weight 
loss are responsible for the observed changes in LV dias-
tolic function.
Comparison with literature
Some studies have investigated the effect of liraglutide 
on LV diastolic function. Nystrom et  al. [26] found no 
change in echocardiography-derived indices of myo-
cardial relaxation, E/Ea or LV ejection fraction in their 
non-blinded randomized study with 62 DM2 patients 
with subclinical heart failure receiving either liraglu-
tide or glimepiride treatment. A double-blind rand-
omized trial in 33 patients with DM2 who underwent a 
16  week exercise program with addition of either lira-
glutide or placebo, showed significantly lower E/Ea in 
liraglutide treated patients [27]. Lastly, in two small non-
randomized studies in patients with DM2, the effect of 
liraglutide was evaluated after 6  months using echocar-
diography. These studies showed a decrease in E/Ea [28] 
and improved Ea [28, 29]. The results of our placebo-
controlled double-blind randomized study confirm the 
finding of some preliminary studies to date that 6-month 
therapy with liraglutide showing lower E/Ea. With regard 
to LV systolic function, not surprisingly, most studies 
have been performed in HFrEF patients with or with-
out DM2 [30, 31]. In HFrEF GLP-1RA therapy has been 
shown to have no effect on LV systolic function, although 
there was a trend towards more frequent hospitalisation 
for heart failure in the study by Margulies et al. [31]. The 
small but significant decline in LV ejection fraction in our 
study is to our knowledge the first study reporting this 
effect of liraglutide in a DM2 population without prior 
cardiovascular disease.
Clinical implications
The LEADER trial has shown that liraglutide reduces 
major adverse cardiovascular event rate (MACE) as 
compared to placebo in patients with  DM2 [32]. The 
mechanisms responsible for GLP-1RAs beneficial effect 
on macrovascular diabetes complications remain to be 
established. Besides improvement of traditional car-
diovascular risk factors, GLP-1RA treatment has been 
shown to reduce atherosclerotic plaque formation in 
mice by modulating macrophage phenotype [33], and 
reducing pro-inflammatory cytokines on a systemic 
level in conjunction with decreased leucocyte adhesion 
and extravasation into the vascular wall [34]. In addi-
tion, a direct effect of GLP-1RA on endothelial cells of 
injured mouse femoral arteries has been described that 
pointed towards suppression of restenosis via nitric oxide 
[35]. Although reduction in cardiovascular event rate 
is the most important factor for improving prognosis 
of patients with DM2, it is important to note that heart 
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Fig. 4 Pressure-volume relation. The LV filling pressure estimate E/
Ea plotted against LV end-diastolic pressure (LVEDV). Liraglutide 
treatment (squares; blue = baseline, red = follow-up) results in a 
lower E/Ea and LVEDV, whereas placebo treated patients (circles; 
blue = baseline, red = follow-up) have higher E/Ea and LVEDV at 
follow-up then at baseline. Note that the shift in pressure volume 
curve is in opposite directions for liraglutide versus placebo. There 
was a tendency towards improved compliance in the liraglutide 
group
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failure was not amongst the primary endpoints of the 
LEADER trial and other cardiovascular safety trials. As 
such, heart failure in patients with DM2 has been pos-
tulated to be the forgotten diabetes complication after 
microvascular and macrovascular complications [6]. This 
study shows that liraglutide has a significant effect on LV 
diastolic function. This study shows that short-term use 
of liraglutide is safe in DM2 patients with LV diastolic 
dysfunction without heart failure (symptoms). We argue 
against routine evaluation of cardiac function with imag-
ing in these patients, because clinical implications for 
the individual patient are currently lacking. It is impor-
tant to note that HFpEF patients with New York Heart 
Association class III or IV were excluded in the present 
study. Since these stages are accompanied by higher E/Ea, 
effects of GLP-1RA therapy in this group of patients can-
not be extrapolated from our study. Since these patients 
are dependent on increased E/Ea for adequate LV filling, 
liraglutide might even risk exacerbation of heart failure 
symptoms and decompensation in this particular sub-
group of patients.
Limitations
First, the relatively low sample size was calculated to 
detect differences in Edec and LV ejection fraction. Other 
primary outcome measures were not included in sam-
ple size calculation. We did indicate the other indices of 
diastolic and systolic function as primary because they 
are very strongly causally linked to Edec and ejection 
fraction. Therefore, we did not correct for multiple test-
ing. As a result of low sample size, there was an uneven 
distribution of BMI (slightly higher in liraglutide) and 
nephropathy (higher prevalence  in placebo). Although 
BMI [36] and albuminuria [37] are associated with LV 
diastolic dysfunction, it is unlikely that this affects study 
outcome because differences are relatively small. More-
over, ANOVA analysis tests the differences between 
groups of within-group changes between baseline and 
follow-up, with correction for between-group differences 
at baseline. A second limitation is that we have chosen 
not to include LV diastolic dysfunction in the inclusion 
criteria of the study because there are no known cut-off 
values for LV diastolic dysfunction assessed with CMR. 
It is very likely that in our study population with mean 
diabetes duration of 11  years, poor glycaemic control, 
and high prevalence of hypertension, the vast majority of 
patients had LV diastolic dysfunction [1, 2, 6]. The third 
limitation regards the use of CMR. The reason CMR was 
used is that it is known for its excellent intra-observer 
reproducibility [11], and CMR is considered the gold 
standard for LV function and structure. CMR assessment 
of LV diastolic function has been shown to be a good 
alternative for echocardiography [10, 14]. It should be 
noted though that values for diastolic and systolic func-
tion as derived from CMR are not interchangeable with 
echocardiography [10, 11]. With regard to assessment 
of Ea, the relatively low temporal resolution of CMR as 
compared to echocardiography might have resulted in 
a lower power to detect significant differences. Another 
possible limitation is the relatively low sample size that 
does not facilitate reliable subgroup analyses.
Conclusions
In conclusion, this study provides evidence that the GLP-
1RA liraglutide influences both left ventricular diastolic 
and systolic function by unloading the left ventricle in 
patients with DM2. Because elevated left ventricular fill-
ing pressure is a driver for diabetic cardiomyopathy, an 
interesting hypothesis is that liraglutide could postpone 
the onset of HFpEF and concomitant morbidity and mor-
tality. Liraglutide does not appear to have a direct effect 
on myocardial relaxation properties. The results of this 
study emphasize that larger studies specifically focus-
ing on cardiac function are warranted in patients with 
DM2 with and without cardiovascular disease, including 
HFpEF. These studies will contribute to a more a com-
plete understanding of cardiovascular benefit and safety 
of GLP-1RA therapy.
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